BRPI0804623A2 - uso de albumina humana terapêutica para a preparação de um fármaco para o tratamento de pacientes sofrendo de distúrbios cognitivos - Google Patents

uso de albumina humana terapêutica para a preparação de um fármaco para o tratamento de pacientes sofrendo de distúrbios cognitivos

Info

Publication number
BRPI0804623A2
BRPI0804623A2 BRPI0804623-9A BRPI0804623A BRPI0804623A2 BR PI0804623 A2 BRPI0804623 A2 BR PI0804623A2 BR PI0804623 A BRPI0804623 A BR PI0804623A BR PI0804623 A2 BRPI0804623 A2 BR PI0804623A2
Authority
BR
Brazil
Prior art keywords
drug
preparation
treatment
patients suffering
human albumin
Prior art date
Application number
BRPI0804623-9A
Other languages
English (en)
Inventor
Victor Grifols Roura
Original Assignee
Grifols Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grifols Sa filed Critical Grifols Sa
Publication of BRPI0804623A2 publication Critical patent/BRPI0804623A2/pt
Publication of BRPI0804623B1 publication Critical patent/BRPI0804623B1/pt
Publication of BRPI0804623B8 publication Critical patent/BRPI0804623B8/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38Albumins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

USO DE ALBUMINA HUMANA TERAPêUTICA PARA A PREPARAçãO DE UM FáRMACO PARA O TRATAMENTO DE PACIENTES SOFRENDO DE DISTúRBIOS COGNITIVOS. A presente invenção refere-se ao uso de albumina humana terapêutica para a preparação de um fármaco para o tratamento de pacientes sofrendo de distúrbios cognitivos. A invenção é baseada no uso de albumina humana terapêutica para a preparação de um fármaco para o tratamento de pacientes sofrendo de distúrbios cognitivos, em que o modelo de administração do fármaco inclui a administração ao paciente por um mínimo de três vezes sucessivas, de uma quantidade terapeuticamente eficiente de albumina terapêutica humana por meio de troca de plasma e/ou de perfusão intravenosa, independente do conteúdo de A<225> no sangue do paciente.
BRPI0804623A 2007-10-26 2008-10-23 uso de albumina humana terapêutica para a preparação de um fármaco para o tratamento de pacientes sofrendo de distúrbios cognitivos BRPI0804623B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200702831A ES2332846B1 (es) 2007-10-26 2007-10-26 Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos.
ES200702831 2007-10-26

Publications (3)

Publication Number Publication Date
BRPI0804623A2 true BRPI0804623A2 (pt) 2009-06-30
BRPI0804623B1 BRPI0804623B1 (pt) 2020-02-11
BRPI0804623B8 BRPI0804623B8 (pt) 2021-05-25

Family

ID=40583637

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0804623A BRPI0804623B8 (pt) 2007-10-26 2008-10-23 uso de albumina humana terapêutica para a preparação de um fármaco para o tratamento de pacientes sofrendo de distúrbios cognitivos

Country Status (17)

Country Link
US (1) US7851446B2 (pt)
EP (1) EP2111868B1 (pt)
JP (1) JP5437619B2 (pt)
CN (1) CN101417123B (pt)
AR (1) AR068901A1 (pt)
AU (1) AU2008233025B8 (pt)
BR (1) BRPI0804623B8 (pt)
CA (1) CA2641830C (pt)
CL (1) CL2008003133A1 (pt)
ES (2) ES2332846B1 (pt)
HK (1) HK1126689A1 (pt)
MX (1) MX2008013635A (pt)
NZ (1) NZ572131A (pt)
PL (1) PL2111868T3 (pt)
PT (1) PT2111868E (pt)
RU (1) RU2414925C2 (pt)
UY (1) UY31418A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10112000B2 (en) 2010-07-08 2018-10-30 Asahi Kasei Medical Co., Ltd. Method for reducing amyloid beta concentration in blood
US10525107B2 (en) 2016-08-18 2020-01-07 Alkahest, Inc. Blood plasma fractions as a treatment for aging-associated cognitive disorders
EP3484502B1 (en) * 2016-08-18 2021-08-25 Alkahest, Inc. Blood plasma fractions as a treatment for aging-associated cognitive disorders
US11040068B2 (en) 2017-04-26 2021-06-22 Alkahest, Inc. Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
BR112019022402A2 (pt) * 2017-04-26 2020-05-19 Alkahest Inc regime de dosagem para tratamento de comprometimentos cognitivo e motor com plasma sanguíneo e produtos de plasma sanguíneo
AU2019306477A1 (en) * 2018-07-20 2021-02-11 Alkahest, Inc. Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
EP3643319A1 (en) * 2018-10-25 2020-04-29 Grifols Worldwide Operations Limited Use of low volume plasma exchange for the treatment of alzheimer's disease in early and middle stages
CN113056275A (zh) 2018-10-26 2021-06-29 万能溶剂有限公司 血浆和血浆组分用于改善疼痛、伤口愈合和术后恢复的用途
CA3215030A1 (en) * 2021-04-30 2022-11-03 Victor Grifols Roura Use of therapeutic plasma exchange and low volume plasma exchange for the treatment of a cognitive impairment

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3612137A1 (de) 1986-04-10 1987-10-15 Biotest Pharma Gmbh Steriles plasmaaustauschmittel
US5112298A (en) 1990-06-25 1992-05-12 Baxter International Inc. Apheresis method and device
US5178603A (en) 1990-07-24 1993-01-12 Baxter International, Inc. Blood extraction and reinfusion flow control system and method
US6627151B1 (en) * 1997-06-13 2003-09-30 Helmut Borberg Method for treatment diseases associated with a deterioration of the macrocirculation, microcirculation and organ perfusion
JP4851676B2 (ja) 2000-05-23 2012-01-11 ザ ユニバーシティ オブ サザン カリフォルニア アルツハイマー病におけるldlレセプタータンパク質1(lrp−1)の役割
EP1370240A4 (en) * 2001-03-02 2004-09-22 Neuron Therapeutics Inc NEUROPROTECTOR FORMULATIONS AND METHOD
US20050227941A1 (en) 2001-12-17 2005-10-13 Karen Duff Sequestration of ass in the periphery in the absence of immunomodulating agent as a therapeutic approach for the treatment or prevention of beta-amyloid related diseases
US7692011B2 (en) 2002-10-04 2010-04-06 Prana Biotechnology Limited 8-hydroxy and 8-mercapto quinazolinones
WO2004056318A2 (en) * 2002-12-19 2004-07-08 New York University Method for treating amyloid disease
DK1592439T3 (da) 2003-02-13 2007-09-10 Octapharma Ag Fremgangsmåde til fremstilling af en albuminoplösning
JP2007528857A (ja) 2003-07-11 2007-10-18 ミリアド ジェネティクス, インコーポレイテッド アルツハイマー病の処置のための薬学的方法、投与レジメンおよび投薬形態
AT413336B (de) * 2003-09-12 2006-02-15 Mattner Frank Dr Apherese-vorrichtung
US20050182044A1 (en) 2004-02-17 2005-08-18 Bruinsma Gosse B. Combinatorial therapy with an acetylcholinesterase inhibitor and (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3,-b]indol-5-yl phenylcarbamate
AT500483B1 (de) 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
US7436304B1 (en) 2005-07-19 2008-10-14 Visible Assets, Inc Evidence tracking

Also Published As

Publication number Publication date
CN101417123B (zh) 2012-06-27
JP5437619B2 (ja) 2014-03-12
CA2641830C (en) 2013-07-16
JP2009108059A (ja) 2009-05-21
US20090111740A1 (en) 2009-04-30
CN101417123A (zh) 2009-04-29
ES2332846A1 (es) 2010-02-12
PL2111868T3 (pl) 2014-01-31
ES2332846B1 (es) 2010-07-08
BRPI0804623B8 (pt) 2021-05-25
BRPI0804623B1 (pt) 2020-02-11
NZ572131A (en) 2010-06-25
MX2008013635A (es) 2009-05-11
ES2428698T3 (es) 2013-11-08
AU2008233025B2 (en) 2013-06-27
RU2414925C2 (ru) 2011-03-27
CA2641830A1 (en) 2009-04-26
PT2111868E (pt) 2013-10-17
UY31418A1 (es) 2009-05-29
EP2111868A1 (en) 2009-10-28
CL2008003133A1 (es) 2009-08-07
AU2008233025A1 (en) 2009-05-14
AU2008233025B8 (en) 2013-07-25
RU2008141076A (ru) 2010-04-27
US7851446B2 (en) 2010-12-14
HK1126689A1 (en) 2009-09-11
EP2111868B1 (en) 2013-08-21
AR068901A1 (es) 2009-12-16

Similar Documents

Publication Publication Date Title
BRPI0804623A2 (pt) uso de albumina humana terapêutica para a preparação de um fármaco para o tratamento de pacientes sofrendo de distúrbios cognitivos
American Society of Anesthesiologists Task Force on Chronic Pain Management Practice guidelines for chronic pain management: an updated report by the American Society of Anesthesiologists Task Force on Chronic Pain Management and the American Society of Regional Anesthesia and Pain Medicine
JP2022009125A5 (pt)
NZ597378A (en) Treatment of multiple sclerosis with laquinimod
BRPI0820800A2 (pt) Dispositivo médico implantável para liberação controlada de droga, e, métodos para administração de uma droga na bexiga de um paciente e para tratar a bexiga em um paciente
EP2216024A3 (en) Use of Ranolazine for the treatment of cardiovascular diseases
BR112012011575A2 (pt) sistema integrado e extensível de anestesia
WO2007109006A3 (en) Infusion device capable of providing multiple liquid medicaments
WO2008022189A3 (en) Administration of high potency platinum compound formulations by inhalation
EA200700214A1 (ru) Мемантин в качестве дополнительной терапии к атипичным антипсихотическим средствам у больных шизофренией
BRPI0806392A8 (pt) uso de aclidínio, aclidínio, método de tratamento ou prevenção e composição farmacêutica
EP1849462A3 (en) A method of alleviating signs and symptons of Spasticity
Chen et al. Efficacy and safety of dexmedetomidine versus propofol for the sedation of tube-retention after oral maxillofacial surgery
JP2010518164A5 (pt)
CY1115269T1 (el) Χρηση ανταγωνιστων οπιοειδων για την παρασκευη ενος φαρμακου στη θεραπευτικη αγωγη εκφυλιστικων ασθενειων του αμφιβληστροειδους
AU2016208779B2 (en) Cebranopadol for treating pain in subjects with impaired hepatic and/or impaired renal function
BR112014004339A2 (pt) suspensão oral
Fyneface-Ogan et al. Anaesthetic management of a super morbidly obese patient for total abdominal hysterectomy: a few more lessons to learn
Cangemi Jr Administration of general anesthesia for outpatient orthognathic surgical procedures
RU2006101061A (ru) Азенапин для лечения шизофрении у пациентов с избыточной массой тела или предрасположенностью к избыточной массе тела
Usichenko et al. Auricular acupuncture
Ohshita et al. Anesthetic management of a patient with multiple sclerosis
NZ599227A (en) Therapeutic agent for chronic pain
JP2010519274A5 (pt)
Winter et al. 0561 Solriamfetol Real World Experience Study: Safety, Efficacy, and Follow-Up for Patients with Obstructive Sleep Apnea in Germany

Legal Events

Date Code Title Description
B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]
B25G Requested change of headquarter approved

Owner name: GRIFOLS, S.A. (ES)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 11/02/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/10/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF